Statement: There are a total of 14 cases of neutropenia related adverse events in the primary trial across both cohorts.
Primary_evidence: Adverse Events 1:   Total: 14/76 (18.42%)   Neutropenia 10/76 (13.16%)   Febrile neutropenia 1/76 (1.32%)   Anaemia 0/76 (0.00%)   Thrombocytopenia 0/76 (0.00%)   Cardiopulmonary failure 0/76 (0.00%)   Optic ischaemic neuropathy 0/76 (0.00%)   Bowel peristalsis increased 1/76 (1.32%)   Colitis 0/76 (0.00%)   Diarrhoea 0/76 (0.00%)   Gastritis 0/76 (0.00%)   Nausea 0/76 (0.00%) Adverse Events 2:   Total: 12/76 (15.79%)   Neutropenia 2/76 (2.63%)   Febrile neutropenia 1/76 (1.32%)   Anaemia 0/76 (0.00%)   Thrombocytopenia 0/76 (0.00%)   Cardiopulmonary failure 1/76 (1.32%)   Optic ischaemic neuropathy 1/76 (1.32%)   Bowel peristalsis increased 0/76 (0.00%)   Colitis 1/76 (1.32%)   Diarrhoea 0/76 (0.00%)   Gastritis 0/76 (0.00%)   Nausea 1/76 (1.32%)